CD33 and acute myeloid leukemia: Despite similar CD33 expression levels between specimens from patients with newly diagnosed AML (n = 12) and those with relapsed/refractory disease (n = 13), the cytotoxic effects with AMG 330 were greater in specimens derived from patients with newly diagnosed AML.